Together We Can Stop Diabetes
Expanding Research to Advance Treatment and a Cure
Robert E. Ratner, MD FACP, FACE, Chief Scientific & Medical
Officer
Tamara Darsow, PhD Vice-President of Research
Tamara Darsow, PhD Vice-President of Research
Betsy Seaquist, MD Vice President, Medicine and Science
John Anderson, MD President-Elect, Medicine and Science
Vivian Fonseca, MD President, Medicine and Science
Sam Dagogo-Jack, MD Chair, Research Grant Review and BOD member
Al Powers, MD Chair, Research Policy Committee
Vincent Poitout, PhD, DVM Research Policy Committee and BOD member
Strategic Objective for Research Expand the field of diabetes research to accelerate
progress toward a cure and improved treatments
By the end of 2015: • Increased number of career development award
recipients who receive subsequent federal funding in the field of diabetes research
• Increased federal funding for diabetes research • Increased Association funding for diabetes research
The American Diabetes Association has been supporting diabetes research in the academic community for more
than half a century, significantly contributing to the diabetes research landscape.
Since inception of the Program in 1952
– Nearly 4,000 research projects have been funded
– More than $600 million has been invested in diabetes research
In 2011 the Program supported: – Nearly $34.6 million in diabetes research
– More than 400 active research projects
– 139 leading academic research institutions
Research Program Successes
• Publications per award 6
• Receive patents 17%
• Receive promotions 56%
• Remain in diabetes research 98%
• Receive recognition awards 47%
85% of investigators received subsequent federal funding to support their work Investigators leveraged Association support into a 7.5 fold increase in funding from other sources Association funding provides the seed for expanding the field of diabetes research
Research Program Successes Panel
Sam Dagogo-Jack, MD
Chair, Research Grant Review and BOD member
Al Powers, MD
Chair, Research Policy Committee
Vincent Poitout, PhD, DVM
Research Policy Committee and BOD member
Kenneth Cusi, MD University of Florida College of Medicine Clinical Translational Award
Role of Early Screening and Intervention for Fatty Liver Disease (NAFLD) in a Predominantly Hispanic Population with Type 2 Diabetes Mellitus (T2DM)
Chih-Pin Liu, Ph.D. City of Hope, Beckman Research Institute
Basic Science Award
Tolerance Induction and Inhibition of Type 1 Diabetes
Alyssa H. Hasty, Ph.D. Vanderbilt University Medical Center
ADA-Ethicon Endosurgery/Covidien Research Award in Bariatric Surgery and Diabetes
Impact of Bariatric Surgery on Resolution of Inflammation in Adipose Tissue
I’m Here to Stop Diabetes
Robert E. Ratner, MD FACP, FACE, Chief Scientific & Medical
Officer
Communication and Translation
Accelerating Research Advances to Patients
Research is Central to the Mission
Professional Resources Scientific Sessions
Professional education Peer-reviewed journals
DiabetesPro
Medical Information Clinical Practice Recommendations
(treatment guidelines) Medical publications
Advocacy Research support
Diabetes prevention and care Legal advocacy and support
Legislative action
Communities Community health education programs
Center for Information & Community Support
Forecast magazine Diabetes.org
RESEARCH Direct research
funding
US Diabetes Therapeutic Advances
GLP-1R agonist
1920 1990 2000 2010 1970
Insulin SFU
Pramlintide
DPP-4
Bromocript
1960 1980
1st ADA Standards of Care 1989
TZD
αGlucosidase inhibitor
Metformin
Rapid-acting insulin
Meglitinide
Basal insulin
Transformation of Diabetes Management
• Beef/Pork Insulin and SFUs
• Average HbA1c ~ 9%
• Complications -common, etiology not clear
• ADA treatment algorithm
• Multiple oral/injection options
• Average HbA1c ~ 7.5%
• Complications -less frequent, etiology(ies) well-defined
1980 2012
Type 2 Diabetes
Transformation of Diabetes Management
1980 2012
Type 1 Diabetes
• Animal Insulins
• Average HbA1c >9%
• Life Expectancy-reduced
• Hypoglycemic Episodes
• Minimal Monitoring Methods
• Complications
• Childbearing?
• Human and analog insulins, pens or pumps, basal and mealtime
• CGMS, Self Glucose Monitoring
• Average HbA1c < 8%
• Life Expectancy-near normal
Professional Journals
Diabetes Basic Research with circulation of 5,000
Rank 1st among diabetes journals, Impact factor of 8.3
2.3 million online visits with 5.5 million total page views
Diabetes Care Clinical Research with circulation of 12,000
Rank 2nd among diabetes journals, Impact factor
Clinical Diabetes – Target audience of primary care physicians – Circulation: 29,000 – 713,000 online visits with 1.3 million page
views Diabetes Spectrum
– Target audience of diabetes educators, NPs, and other HCP
– Circulation: 5,500 – 550,000 online visits with 920K total page
views
Professional Journals
Translation of Research Findings
Betsy Seaquist, MD
Vice President, Medicine and Science
John Anderson, MD
President-Elect, Medicine and Science
Vivian Fonseca, MD
President, Medicine and Science
I’m Here to Stop Diabetes